Purpose: While immune checkpoint inhibitors are disrupting the management of patients with
cancer, anecdotal occurrences of rapid progression (ie, hyperprogressive disease or HPD) …

Importance The data reported herein were accepted for assessment by the US Food and
Drug Administration for Biologics License Application under priority review to establish the …

Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody
that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on …

Background Because responses of patients with cancer to immunotherapy can vary in success,
innovative predictors of response to treatment are urgently needed to improve treatment …

Purpose The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A),
a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell …

High-throughput genomic analyses may improve outcomes in patients with advanced cancers.
MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. …

Background The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic
castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status …

Background Major advances have been achieved in the characterization of early breast cancer
(eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes…

Background Androgen receptor (AR) signalling remains critically important in metastatic
castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III trials, showing a …

Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of
a subset of patients across multiple solid tumour types, but other patients can have a …